Hypophosphatasia Treatment Global Market Report 2024

The hypophosphatasia treatment market size has grown steadily in recent years. It will grow from $2.68 billion in 2023 to $2.81 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth observed in the historical period can be attributed to several factors, including limited treatment options, increased awareness of the condition, the globalization of clinical trials, development in healthcare infrastructure, and investments and funding in the field.

The hypophosphatasia treatment market size is expected to see strong growth in the next few years. It will grow to $3.45 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The anticipated growth in the forecast period can be attributed to emerging therapies, a growing patient pool, trends in precision medicine, government initiatives, and increased awareness of the disease. Major trends expected in the forecast period include advancements in therapeutic approaches, increased focus on research and development initiatives, market expansion and global reach, collaborations and partnerships within the industry, and considerations of the evolving regulatory landscape.

The anticipated growth of the hypophosphatasia treatment market is driven by the increasing investments in biomedical research activities. These investments involve verifying biomedical science theories through scientific research techniques and expanding knowledge about unique aspects of human health. Biomedical research investments play a crucial role in developing new drugs and therapies for the efficient and improved treatment of hypophosphatasia, a rare inherited bone disorder. As reported by the Centers for Medicare & Medicaid Services in September 2023, national health expenditure in the United States experienced a 2.7% growth in 2021, reaching $4.3 trillion. The average projected growth in national health expenditure from 2022 to 2031 is 5.4%, surpassing the average GDP growth of 4.6%. This trajectory is expected to result in an increased health spending share of GDP from 18.3% in 2021 to 19.6% in 2031. Thus, the rise in biomedical research investments is a significant driver for the growth of the hypophosphatasia treatment market.

The anticipated growth of the hypophosphatasia treatment market is also attributed to the increasing geriatric population. The geriatric population, comprising individuals aged 65 years and above, contributes to the demand for hypophosphatasia-related healthcare services. This includes early diagnosis and long-term management, driving advancements in understanding and treating this condition within the aging demographic. According to the World Health Organization (WHO) report in October 2022, one in six people worldwide is expected to be 60 or older by 2030, and by 2050, there will be 2.1 billion people aged 60 or older. Therefore, the growing geriatric population is a significant factor propelling the hypophosphatasia treatment market.

Strategic partnerships have emerged as a noteworthy trend in the hypophosphatasia market, with major companies focusing on collaborations to strengthen their market position. For example, in November 2021, Genomenon Inc. collaborated with AstraZeneca to enhance access to crucial data for detecting and managing rare disorders, including hypophosphatasia. The goal is to provide genetic testing facilities with the necessary information to identify rare diseases. Additionally, in June 2021, Aruvant Sciences partnered with Aldevron Madison LLC to aid in developing potentially curative medicines for conditions such as sickle cell anemia and hypophosphatasia.

Major companies operating in the hypophosphatasia treatment market are adopting a strategic partnership approach to enhance supply chain resilience. In August 2023, AdventHealth partnered with Medline Industries LP to optimize the supply chain, leveraging the capabilities of a national health system and an industry partner. This collaboration enhances inventory control and distribution strategy, promoting improved patient outcomes and cost optimization. This structured approach strengthens the supply chain's resilience and establishes a framework to support future growth.

In July 2021, AstraZeneca acquired Alexion Pharmaceutical Inc. for an undisclosed amount, marking the company's entry into the development of medications for uncommon diseases, including hypophosphatasia. Alexion Pharmaceutical Inc., a U.S.-based manufacturer of medicine for hypophosphatasia treatment, became part of AstraZeneca through this acquisition.

Major companies operating in the hypophosphatasia treatment market report are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group plc, Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Prior Company Ltd., Enobia Pharma Corporation, AstraZeneca plc, Rallybio Corporation, AbCellera Biologics Inc., Inozyme Pharma Inc., Aruvant Sciences Pte. Ltd., Alexion Pharmaceuticals Inc., Asfotase Alfa, Merck Co. & KGaA, Kyowa Kirin Co.Ltd., Shire plc, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Roche Holding AG, Johnson & Johnson Services Inc., AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc., Incyte Corporation, Ipsen S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc.

North America was the largest region in the hypophosphatasia treatment market in 2023. The regions covered in the hypophosphatasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypophosphatasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The major types of hypophosphatasia disorders include odontohypophosphatasia, pseudohypophosphatasia, and others, and they can be treated through various methods such as enzyme replacement therapies, medications, and surgeries. Odontohypophosphatasia is a specific subtype of hypophosphatasia (HPP) characterized by lower activity of unfractionated serum alkaline phosphatase, premature exfoliation of primary and permanent teeth, and severe dental caries. Treatment methods may be administered orally or through injections. Distribution channels for these treatments include hospital pharmacies, online pharmacies, and retail pharmacies, catering to end users such as hospitals, homecare, specialty clinics, among others.

The hypophosphatasia treatment market research report is one of a series of new reports that provides hypophosphatasia treatment market statistics, including hypophosphatasia treatment industry global market size, regional shares, competitors with a hypophosphatasia treatment market share, detailed hypophosphatasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hypophosphatasia treatment industry. This hypophosphatasia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.